NEKTAR THERAPEUTICS - REZOLVE-AD STUDY MEETS ALL PRIMARY AND KEY SECONDARY ENDPOINTS FOR REZPEGALDESLEUKIN 24 ΜG/KG Q2W

Reuters · 3d ago

Please log in to view news